May 2024 in “Psychiatric News” Weight-loss drugs are not linked to suicidal thoughts.
59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
September 2025 in “Cureus” GLP-1 receptor agonists may cause hair loss, but more research is needed.
September 2024 in “Journal of the American Academy of Dermatology” Semaglutide does not significantly increase the risk of hair loss.
October 2025 in “JEADV Clinical Practice” GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.